Memorial Sloan Kettering Cancer Center: 100% Complete Response Rate in MMRd Locally Advanced Rectal Cancer Seen in Pivotal 'Immunoablative' Neoadjuvant Immunotherapy Clinical Trial
June 06, 2022
June 06, 2022
NEW YORK, June 6 (TNSjou) -- The Memorial Sloan Kettering Cancer Center issued the following news release on June 5, 2022:
Breakthrough findings were presented at the 2022 ASCO Annual Meeting and published in The New England Journal of Medicine today by researchers at Memorial Sloan Kettering Cancer Center (MSK) confirming a clinical complete response in all 12 patients who received the immunotherapy treatment dostarlimab as a first-line treatment for mismatch repair-deficient (MMRd . . .
Breakthrough findings were presented at the 2022 ASCO Annual Meeting and published in The New England Journal of Medicine today by researchers at Memorial Sloan Kettering Cancer Center (MSK) confirming a clinical complete response in all 12 patients who received the immunotherapy treatment dostarlimab as a first-line treatment for mismatch repair-deficient (MMRd . . .